University of California San Francisco
Give to UCSF<p>Dramatically positioned at Parnassus Heights, the Ray and Dagmar Dolby Regeneration Medicine Building at UCSF is gaining national recognition as a stunning architectural and engineering feat.</p>
Among those cheering the recent opening of the new stem cell science building at UCSF were two patient advocates who have a personal connection to advancing the field of regenerative medicine.
A new video depicts the energy and excitement of the grand opening of the Ray and Dagmar Dolby Regeneration Medicine Building on the UCSF Parnassus campus on Feb. 9.
Leading scientists from California companies discussed groundbreaking clinical trials of stem cell therapies during a recent scientific symposium to celebrate the opening of the Ray and Dagmar Dolby Regeneration Medicine Building at UCSF.
The bold and innovative stem cell research building on the UCSF Parnassus campus stands as a testament to the architectural genius of Raphael Viñoly and public and private support of UCSF's pioneering program in regeneration medicine.
Acclaimed stem cell researcher Shinya Yamanaka, who is a professor of anatomy at UCSF, can add two more prestigious prizes to his already impressive resume.
UCSF celebrates the opening of an architecturally unique stem cell building, a milestone in the history of UCSF’s pioneering stem cell research program, one of the largest and most comprehensive of its kind in the United States.
Ray and Dagmar Dolby this week donated $20 million to the University of California, San Francisco to provide funding for a stem cell building on the Parnassus campus.
UCSF researchers have tackled a decade-long scientific conundrum, and their discovery is expected to lead to significant advances in using stem cells to treat genetic diseases before birth.
UCSF researchers have shown for the first time that the human fetal immune system arises from an entirely different source than the adult immune system, and is more likely to tolerate than fight foreign substances in its environment.
For patients with glioma, the most common primary brain tumor, new findings may explain why current therapies fail to eradicate the cancer. A UCSF-led team of scientists has identified for the first time that progenitor rather than neural stem cells underly a type of glioma called oligodendroglioma.
Seven of UCSF’s health care experts will share their wisdom on Wednesday during the cloud computing conference known as Dreamforce 2010 at San Francisco’s Moscone Center.
A lawsuit and inaction by Congress threaten federally funded embryonic stem cell research at UCSF and across the country.
Scientists are reporting the first direct evidence that a subtle change in the physical properties of a tissue can affect its function.
Amy Pyle, a veteran journalist with more than 20 years experience in communications, has joined UCSF as executive director of news and media relations.
Ophir Klein wants to use stem cells to grow teeth. Because teeth are simple in comparison to large, vital organs, they may serve as a proving ground for regenerative medicine.
<p>Scientists this week are moving into the headquarters for the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at UCSF, where they will continue to advance a field transformed by the revolutionary achievement of Shinya Yamanaka.</p>
UCSF scientists have received two grants from the California Institute for Regenerative Medicine to refine their human embryonic stem cell-based strategies for treating neurological diseases and liver failure.
The National Institutes of Health (NIH) on September 30 announced 52 highly competitive awards for high-risk, high-payoff research for young biomedical scientists, and UCSF tops California institutions with four recipients.
The UCSF Diabetes Center symposium marks its 10th anniversary.
The U.S. Department of Justice declined to consent to the University of California’s motion to intervene in Sherley v. Sebelius, the case regarding federal funding for human embryonic stem cell (hESC) research, on which UC had made a motion to the U.S. Federal Court of Appeals on Sept. 20.
The University of California filed a motion Sept. 20 with the U.S. Federal Court of Appeals to intervene in Sherley v. Sebelius, the case regarding whether federal funds could be used for human embryonic stem cell (hESC) research. UC is the nation’s first research institution to formally seek to intervene in the pending lawsuit.
UCSF is co-sponsoring a symposium on September 27 and 28 to provide scientists and physicians with the “nuts and bolts” of translating stem cell science into cell-based products for clinical trials.